Ֆլուտամիդ

main_info

  • trade_name:
  • Ֆլուտամիդ
  • dosage:
  • 250մգ(84/4x21/) բլիստերում
  • pharmaceutical_form:
  • դեղահատեր
  • prescription_type:
  • Դեղատոմսով
  • medicine_domain:
  • Human
  • medicine_type:
  • Allopathic

documents

localization

  • country:
  • Ֆլուտամիդ
    አርሜኒያ
  • language:
  • አማርኛ

other_info

status

  • source:
  • Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում - Armenia
  • last_update:
  • 31-05-2018

15-4-2019

H&M Bathrobes recalled due to Flammability Hazard

H&M Bathrobes recalled due to Flammability Hazard

Health Canada's sampling and evaluation program has determined that these products do not meet the flammability requirements for children's sleepwear under Canadian law.

Health Canada

11-4-2019

"I'M SLEEPING IN" bathrobe recalled due to flammability hazard

"I'M SLEEPING IN" bathrobe recalled due to flammability hazard

Health Canada's sampling and evaluation program has determined that these products do not meet the flammability requirements for children's sleepwear under Canadian law.

Health Canada

8-4-2019

Mini Boo Bamboo Playsuit recalled due to flammability hazard

Mini Boo Bamboo Playsuit recalled due to flammability hazard

Health Canada's sampling and evaluation program has determined that these products do not meet the flammability requirements for children's sleepwear under Canadian law.

Health Canada

5-4-2019

Ergopouch Explorer Sleep Suit Bag recalled due to flammability hazard

Ergopouch Explorer Sleep Suit Bag recalled due to flammability hazard

Health Canada's sampling and evaluation program has determined that these products do not meet the flammability requirements for children's sleepwear under Canadian law.

Health Canada

1-4-2019

Certain articles of Calvin Klein children's sleepwear recalled due to flammability hazard

Certain articles of Calvin Klein children's sleepwear recalled due to flammability hazard

Health Canada's sampling and evaluation program has determined that these products do not meet the flammability requirements for children's sleepwear under Canadian law.

Health Canada

28-3-2019

FDA approves treatment for patients with a type of inflammatory arthritis

FDA approves treatment for patients with a type of inflammatory arthritis

The FDA is approving Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis. This is the first time that the FDA has approved a treatment for non-radiographic axial spondyloarthritis (nr-axSpA). nr-axSpA is a type of inflammatory arthritis that causes inflammation in the spine and other symptoms

FDA - U.S. Food and Drug Administration

26-3-2019

Nest Designs recalls Sleeveless Bamboo Sleep Bag TOG 0.6

Nest Designs recalls Sleeveless Bamboo Sleep Bag TOG 0.6

Health Canada's sampling and evaluation program has determined that these products do not meet the flammability requirements for children's sleepwear under Canadian law.

Health Canada

20-3-2019

Toys"R"Us Canada recalls various Koala Baby 2-Pack Sleepers

Toys"R"Us Canada recalls various Koala Baby 2-Pack Sleepers

Health Canada's sampling and evaluation program has determined that these products do not meet the flammability requirements for children's sleepwear under Canadian law.

Health Canada

18-3-2019

Okaïdi Canada Inc. recalls certain articles of Obaïbi brand sleepwear

Okaïdi Canada Inc. recalls certain articles of Obaïbi brand sleepwear

Health Canada's sampling and evaluation program has determined that these products do not meet the flammability requirements for children's sleepwear under Canadian law.

Health Canada

13-3-2019

Vêtements Orchestra Canada Inc. recalls girls' two-piece"Puppy Love" pyjama sets and"Hello Weekend" nightgowns

Vêtements Orchestra Canada Inc. recalls girls' two-piece"Puppy Love" pyjama sets and"Hello Weekend" nightgowns

Health Canada has established that the recalled products do not meet the flammability requirements for children's sleepwear under Canadian law.

Health Canada

6-3-2019

Y.M. Inc recalls Urban Kids Girls Graphic Pajama Long Sleeve Shirts

Y.M. Inc recalls Urban Kids Girls Graphic Pajama Long Sleeve Shirts

Health Canada's sampling and evaluation program has determined that these products do not meet the flammability requirements for children's sleepwear under Canadian law.

Health Canada

22-2-2019

IKERE Limited recalls ZOOCCHINI UPF50 Baby Cover up

IKERE Limited recalls ZOOCCHINI UPF50 Baby Cover up

As the Baby Cover up is advertised as a bathrobe, it must meet the flammability requirements for children's sleepwear. This product fails to meet these requirements. As a beach robe / cover-up it is not subject to the Children Sleepwear Regulations.

Health Canada

8-2-2019

Kyte BABY LLC recalls Kyte BABY Sleep Bag Walkers

Kyte BABY LLC recalls Kyte BABY Sleep Bag Walkers

The sleep bag with ankle cuffs fails to meet the flammability requirements for children's sleepwear under Canadian Law, therefore posing a risk of burn injuries to children.

Health Canada

19-11-2018

Indigo Books & Music Inc. recalls American Girl WellieWishers Magic Theater Play Tent

Indigo Books & Music Inc. recalls American Girl WellieWishers Magic Theater Play Tent

The play tent does not meet the requirements for tent flammability under Canadian law. The tents could catch fire if exposed to a flame or other ignition source, and pose possible fire and burn hazards to consumers.

Health Canada

18-10-2018

Unauthorized "Surfaz-SN Triple Action Cream" seized from Mississauga store may pose serious health risks

Unauthorized "Surfaz-SN Triple Action Cream" seized from Mississauga store may pose serious health risks

Health Canada seized “Surfaz-SN Triple Action Cream”—an unauthorized skin cream promoted for antifungal, antibacterial and anti-inflammatory use—because it is labelled to contain prescription drugs (betamethasone dipropionate and neomycin sulphate). The product was seized from Kaf African Caribbean Market (2642 Liruma Road, Unit 2A) in Mississauga, Ontario.

Health Canada

3-8-2018

Zithromax, Zmax (azithromycin): FDA Warning - Increased Risk of Cancer Relapse With Long-Term Use After Donor Stem Cell Transplant

Zithromax, Zmax (azithromycin): FDA Warning - Increased Risk of Cancer Relapse With Long-Term Use After Donor Stem Cell Transplant

The antibiotic Zithromax, Zmax (azithromycin) should not be given long-term to prevent a certain inflammatory lung condition in patients with cancers of the blood or lymph nodes who undergo a donor stem cell transplant. Results of a clinical trial found an increased rate of relapse in cancers affecting the blood and lymph nodes, including death, in these patients.

FDA - U.S. Food and Drug Administration

30-7-2018

ANSES recommends that certain populations avoid the consumption of food supplements containing melatonin

ANSES recommends that certain populations avoid the consumption of food supplements containing melatonin

Under the national nutrivigilance scheme, reports of adverse effects likely to be associated with the consumption of food supplements containing melatonin have been brought to the attention of ANSES. A retrospective analysis of these reports, combined with the considerable level of consumption of this type of supplement, led ANSES to conduct an assessment of the potential health risks. In its Opinion of February 2018, the Agency highlighted the existence of populations and situations at risk, for which t...

France - Agence Nationale du Médicament Vétérinaire

25-4-2018

Lamictal (lamotrigine): Drug Safety Communication - Serious Immune System Reaction

Lamictal (lamotrigine): Drug Safety Communication - Serious Immune System Reaction

The FDA is warning that the medicine lamotrigine (Lamictal) for seizures and bipolar disorder can cause a rare but very serious reaction that excessively activates the body’s infection-fighting immune system. This can cause severe inflammation throughout the body and lead to hospitalization and death, especially if the reaction is not diagnosed and treated quickly. As a result, we are requiring a new warning about this risk be added to the prescribing information in the lamotrigine drug labels. The immun...

FDA - U.S. Food and Drug Administration

no_news